|
20 Oct 2023 |
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda
|
|
11 Oct 2023 |
MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus
|
|
10 Oct 2023 |
Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout
|
|
08 Oct 2023 |
Angany announces First-in-Human Clinical Study on ANG-101, a Vaccine Candidate to Treat Cat Allergy
|
|
05 Oct 2023 |
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
|
|
03 Oct 2023 |
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
|
|
29 Sep 2023 |
PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free
|
|
28 Sep 2023 |
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
|
|
28 Sep 2023 |
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
|
|
28 Sep 2023 |
New Study Shows Longhorn Vaccines and Diagnostics’ Universal Influenza Vaccine, LHNVD-105, Generates Broad and Durable Immune Responses in Animal Models
|
|
27 Sep 2023 |
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
|
|
26 Sep 2023 |
Longhorn Vaccines and Diagnostics Presents Data Demonstrating Neutralizing Activity of LHNVD-201 for Covid-19 and Influenza Co-Infections
|
|
20 Sep 2023 |
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
|
|
20 Sep 2023 |
SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01
|
|
19 Sep 2023 |
LinKinVax and Gustave Roussy Announced First Patient Dosed in Phase I/IIa Clinical Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer
|
|
12 Sep 2023 |
Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation srRNA Vaccine
|
|
12 Sep 2023 |
OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology
|
|
12 Sep 2023 |
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
|
|
08 Sep 2023 |
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
|
|
08 Sep 2023 |
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
|
|
07 Sep 2023 |
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
|
|
06 Sep 2023 |
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
|
|
05 Sep 2023 |
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
|
|
05 Sep 2023 |
ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine
|
|
05 Sep 2023 |
ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001
|
